Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting, 64541 [E6-18472]
Download as PDF
<![CDATA[
64541
Federal Register / Vol. 71, No. 212 / Thursday, November 2, 2006 / Notices
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
21 CFR Section
601.91(b)(2)(iii)
1There
1
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Cellular, Tissue and Gene Therapies
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Cellular, Tissue
and Gene Therapies Advisory
Committee.
mstockstill on PROD1PC61 with NOTICES
Total Annual
Records
1
Hours per
Record
1
Total Hours
1
1
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: October 25, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–18445 Filed 11–1–06; 8:45 am]
ACTION:
Annual Frequency
per Recordkeeping
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held by teleconference on November 20,
2006, from 2:15 p.m. to approximately
5 p.m.
Location: National Institutes of Health
(NIH), Bldg. 29, rm. 121, 9000 Rockville
Pike, MD. This meeting will be held by
teleconference. The public is welcome
to attend the meeting at the specified
location. A speakerphone will be
provided at the specified location for
public participation in the meeting.
Important information about
transportation, directions to the NIH
campus, parking, and security
procedures is available on the Internet
at https://www.nih.gov/about/visitor/
index.htm. Visitors must show two
forms of identification, one of which
must be a Government-issued photo
identification such as a Federal
employee badge, driver’s license,
passport, green card, etc. If you are
planning to drive to and park on the
NIH campus, you must enter at the
South Dr. entrance of the campus which
is located on Wisconsin Ave. (the
Medical Center Metro entrance), and
allow extra time for vehicle inspection.
VerDate Aug<31>2005
14:49 Nov 01, 2006
Jkt 211001
Detailed information about security
procedures is located at https://
www.nih.gov/about/visitorsecurity.htm.
Due to the limited available parking,
visitors are encouraged to use public
transportation. (FDA has verified the
Web site addresses, but FDA is not
responsible for any subsequent changes
to the Web sites after this document
publishes in the Federal Register.)
Contact Person: Gail Dapolito or
Rosanna Harvey, Center for Biologics
Evaluation and Research, (HFM–71),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD, 20852,
301–827–0314, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
3014512389. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: On November 20, 2006, the
committee will meet in open session to
hear updates of research programs in the
Laboratory of Immunobiology and the
Laboratory of Immunology, Office of
Biotechnology Products, Center for Drug
Evaluation and Research.
Procedure: On November 20, 2006,
from 2:15 p.m. to approximately 4:30
p.m., the meeting is open to the public.
Interested persons may present data,
information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
November 13, 2006. Oral presentations
from the public will be scheduled
between approximately 3:30 p.m. and
4:30 p.m. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
November 13, 2006.
Closed Committee Deliberations: On
November 20, 2006, from approximately
4:30 p.m. to 5 p.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
committee will discuss a report of
intramural research programs.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Gail Dapolito
at least 7 days in advance of the
meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 27, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning
[FR Doc. E6–18472 Filed 11–1–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Pediatric Oncology Subcommittee of
the Oncologic Drugs Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Pediatric
Oncology Subcommittee of the
Oncologic Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 6, 2006, from 8:30
a.m. to 5 p.m.
Location: Food and Drug
Administration, Center for Drug
Evaluation and Research Advisory
Committee Conference Room, rm. 1066,
5630 Fishers Lane, Rockville, MD.
E:\FR\FM\02NON1.SGM
02NON1
]]>Agencies
[Federal Register Volume 71, Number 212 (Thursday, November 2, 2006)]
[Notices]
[Page 64541]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-18472]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Cellular, Tissue and Gene Therapies Advisory Committee; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
Name of Committee: Cellular, Tissue and Gene Therapies Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held by teleconference on
November 20, 2006, from 2:15 p.m. to approximately 5 p.m.
Location: National Institutes of Health (NIH), Bldg. 29, rm. 121,
9000 Rockville Pike, MD. This meeting will be held by teleconference.
The public is welcome to attend the meeting at the specified location.
A speakerphone will be provided at the specified location for public
participation in the meeting. Important information about
transportation, directions to the NIH campus, parking, and security
procedures is available on the Internet at https://www.nih.gov/about/
visitor/index.htm. Visitors must show two forms of identification, one
of which must be a Government-issued photo identification such as a
Federal employee badge, driver's license, passport, green card, etc. If
you are planning to drive to and park on the NIH campus, you must enter
at the South Dr. entrance of the campus which is located on Wisconsin
Ave. (the Medical Center Metro entrance), and allow extra time for
vehicle inspection. Detailed information about security procedures is
located at https://www.nih.gov/about/visitorsecurity.htm. Due to the
limited available parking, visitors are encouraged to use public
transportation. (FDA has verified the Web site addresses, but FDA is
not responsible for any subsequent changes to the Web sites after this
document publishes in the Federal Register.)
Contact Person: Gail Dapolito or Rosanna Harvey, Center for
Biologics Evaluation and Research, (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD, 20852, 301-827-
0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-
443-0572 in the Washington, DC area), code 3014512389. Please call the
Information Line for up-to-date information on this meeting.
Agenda: On November 20, 2006, the committee will meet in open
session to hear updates of research programs in the Laboratory of
Immunobiology and the Laboratory of Immunology, Office of Biotechnology
Products, Center for Drug Evaluation and Research.
Procedure: On November 20, 2006, from 2:15 p.m. to approximately
4:30 p.m., the meeting is open to the public. Interested persons may
present data, information, or views, orally or in writing, on issues
pending before the committee. Written submissions may be made to the
contact person on or before November 13, 2006. Oral presentations from
the public will be scheduled between approximately 3:30 p.m. and 4:30
p.m. Time allotted for each presentation may be limited. Those desiring
to make formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before November 13, 2006.
Closed Committee Deliberations: On November 20, 2006, from
approximately 4:30 p.m. to 5 p.m., the meeting will be closed to permit
discussion where disclosure would constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will
discuss a report of intramural research programs.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Gail Dapolito at
least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 27, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning
[FR Doc. E6-18472 Filed 11-1-06; 8:45 am]
BILLING CODE 4160-01-S
